Neurology 2001;57:1428-1434
© 2001 American Academy of Neurology
Articles
Use of anti-ICAM-1 therapy in ischemic stroke
Results of the Enlimomab Acute Stroke Trial
Enlimomab Acute Stroke Trial Investigators
*See the Appendix on page 1433 for a list of group members.
Address correspondence and reprint requests to Dr. D. Sherman, Department of Medicine, Mail Code 7883, University of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, TX 78229-3900; e-mail: sherman{at}uthscsa.edu
Background: — There has been recent interest in the possible role of reperfusion-induced inflammation with neuronal injury after stroke. Enlimomab, a murine intercellular adhesion molecule-1 (ICAM-1) antibody, reduces leukocyte adhesion and infarct size in experimental stroke studies. The purpose of the current clinical trial was to evaluate the use of enlimomab after ischemic stroke.
Methods: — A total of 625 patients with ischemic stroke were randomized to receive either enlimomab (n = 317) or placebo (n = 308) within 6 hours of stroke onset. Treatment was given over 5 days. Patients were evaluated at baseline and on days 5 and 90 after initiation of treatment; long-term assessments were carried out after 6 and 12 months. The primary efficacy endpoint was the response to therapy at 90 days on the Modified Rankin Scale; other endpoints included Barthel Index (BI) and NIH Stroke Scale and survival.
Results: — At day 90, the Modified Rankin Scale score was worse in patients treated with enlimomab than with placebo (p = 0.004). Fewer patients had symptom-free recovery on enlimomab than placebo (p = 0.004), and more died (22.2 versus 16.2%). The negative effect of enlimomab was apparent on days 5, 30, and 90 of treatment (p = 0.005). There were significantly more adverse events with enlimomab treatment than placebo, primarily infections and fever. Patients experiencing fever were more likely to have a poor outcome or die.
Conclusions: — The authors conclude that anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke in the model studied and, indeed, may significantly worsen stroke outcome.
This article has been cited by other articles:
|
|
|
|
 
P. Mandava and T. A. Kent
A Method to Determine Stroke Trial Success Using Multidimensional Pooled Control Functions
Stroke,
May 1, 2009;
40(5):
1803 - 1810.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Ginsberg
Current Status of Neuroprotection for Cerebral Ischemia: Synoptic Overview
Stroke,
March 1, 2009;
40(3_suppl_1):
S111 - S114.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. Kadhim, J. Duchateau, and G. Sebire
Cytokines and Brain Injury: Invited Review
J Intensive Care Med,
July 1, 2008;
23(4):
236 - 249.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. G. Schneider, Y. Zhu, T. Coleman, and C. F. Semenkovich
Macrophage 3 Integrin Suppresses Hyperlipidemia-Induced Inflammation by Modulating TNF{alpha} Expression
Arterioscler Thromb Vasc Biol,
December 1, 2007;
27(12):
2699 - 2706.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Saleh, M. Schroeter, A. Ringelstein, H.-P. Hartung, M. Siebler, U. Modder, and S. Jander
Iron Oxide Particle-Enhanced MRI Suggests Variability of Brain Inflammation at Early Stages After Ischemic Stroke
Stroke,
October 1, 2007;
38(10):
2733 - 2737.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The Optimising Analysis of Stroke Trials (OAST) Co
Can We Improve the Statistical Analysis of Stroke Trials?: Statistical Reanalysis of Functional Outcomes in Stroke Trials * OAST Supplemental Appendix I: Statistical Tests Compared (see Table I) * OAST Supplemental Appendix II: Supplementary Analyses * OAST Supplemental Appendix III: Trial Data (see Tables II and III) * OAST Supplemental Appendix IV: Results (see Table IV)
Stroke,
June 1, 2007;
38(6):
1911 - 1915.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al.
Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Circulation,
May 22, 2007;
115(20):
e478 - e534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al.
Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists
Stroke,
May 1, 2007;
38(5):
1655 - 1711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Jander, M. Schroeter, and A. Saleh
Imaging Inflammation in Acute Brain Ischemia
Stroke,
February 1, 2007;
38(2):
642 - 645.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Gee, A. Kalil, C. Shea, and K. J. Becker
Lymphocytes: Potential Mediators of Postischemic Injury and Neuroprotection
Stroke,
February 1, 2007;
38(2):
783 - 788.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Baird
The Forgotten Lymphocyte: Immunity and Stroke
Circulation,
May 2, 2006;
113(17):
2035 - 2036.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C J M Frijns, R Fijnheer, A Algra, J A van Mourik, J van Gijn, and G J E Rinkel
Early circulating levels of endothelial cell activation markers in aneurysmal subarachnoid haemorrhage: associations with cerebral ischaemic events and outcome
J. Neurol. Neurosurg. Psychiatry,
January 1, 2006;
77(1):
77 - 83.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Elkins, T. Khatabi, L. Fung, J. Rootenberg, and S. C. Johnston
Recruiting Subjects for Acute Stroke Trials: A Meta-Analysis
Stroke,
January 1, 2006;
37(1):
123 - 128.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Yonekawa and J. M. Harlan
Targeting leukocyte integrins in human diseases
J. Leukoc. Biol.,
February 1, 2005;
77(2):
129 - 140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. L. Lutsep
Current Status of Hemorrhagic Stroke and Acute Nonthrombolytic Ischemic Stroke Treatment
Stroke,
November 1, 2004;
35(11_suppl_1):
2746 - 2747.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Weir, M. Kaste, K. R. Lees, and for the Glycine Antagonist in Neuroprotection Int
Targeting Neuroprotection Clinical Trials to Ischemic Stroke Patients With Potential to Benefit From Therapy
Stroke,
September 1, 2004;
35(9):
2111 - 2116.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.J. S. Price, D.K. Menon, A.M. Peters, J.R. Ballinger, R.W. Barber, K.K. Balan, A. Lynch, J.H. Xuereb, T. Fryer, J.V. Guadagno, et al.
Cerebral Neutrophil Recruitment, Histology, and Outcome in Acute Ischemic Stroke: An Imaging-Based Study
Stroke,
July 1, 2004;
35(7):
1659 - 1664.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Weaver, J. Leonardi-Bee, F. J. Bath-Hextall, and P. M.W. Bath
Sample Size Calculations in Acute Stroke Trials: A Systematic Review of Their Reporting, Characteristics, and Relationship With Outcome
Stroke,
May 1, 2004;
35(5):
1216 - 1224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. H. Danton and W. D. Dietrich
The Search for Neuroprotective Strategies in Stroke
AJNR Am. J. Neuroradiol.,
February 1, 2004;
25(2):
181 - 194.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Vemuganti, R. J. Dempsey, and K. K. Bowen
Inhibition of Intercellular Adhesion Molecule-1 Protein Expression by Antisense Oligonucleotides Is Neuroprotective After Transient Middle Cerebral Artery Occlusion in Rat
Stroke,
January 1, 2004;
35(1):
179 - 184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Blann, S. K. Nadar, and G. Y.H. Lip
The adhesion molecule P-selectin and cardiovascular disease
Eur. Heart J.,
December 2, 2003;
24(24):
2166 - 2179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C J S Price, E A Warburton, and D K Menon
Human cellular inflammation in the pathology of acute cerebral ischaemia
J. Neurol. Neurosurg. Psychiatry,
November 1, 2003;
74(11):
1476 - 1484.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Krams, K. R. Lees, W. Hacke, A. P. Grieve, J.-M. Orgogozo, and G. A. Ford
Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): An Adaptive Dose-Response Study of UK-279,276 in Acute Ischemic Stroke
Stroke,
November 1, 2003;
34(11):
2543 - 2548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Adams, M. I. Chimowitz, J. S. Alpert, I. A. Awad, M. D. Cerqueria, P. Fayad, and K. A. Taubert
Coronary Risk Evaluation in Patients With Transient Ischemic Attack and Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association
Circulation,
September 9, 2003;
108(10):
1278 - 1290.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Adams, M. I. Chimowitz, J. S. Alpert, I. A. Awad, M. D. Cerqueria, P. Fayad, and K. A. Taubert
Coronary Risk Evaluation in Patients With Transient Ischemic Attack and Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association
Stroke,
September 1, 2003;
34(9):
2310 - 2322.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Naidu, E. S. Fu, E. T. Sutton, L. D. Prockop, and A. Cantor
The Therapeutic Effects of Epidural Intercellular Adhesion Molecule-1 Monoclonal Antibody in a Rabbit Model: Involvement of the Intercellular Adhesion Molecule-1 Pathway in Spinal Cord Ischemia
Anesth. Analg.,
September 1, 2003;
97(3):
857 - 862.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Cherian, G. J. Hankey, J. W. Eikelboom, J. Thom, R. I. Baker, A. McQuillan, J. Staton, and Q. Yi
Endothelial and Platelet Activation in Acute Ischemic Stroke and Its Etiological Subtypes
Stroke,
September 1, 2003;
34(9):
2132 - 2137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Mack, J. Huang, C. Winfree, G. Kim, M. Oppermann, J. Dobak, B. Inderbitzen, S. Yon, S. Popilskis, J. Lasheras, et al.
Ultrarapid, Convection-Enhanced Intravascular Hypothermia: A Feasibility Study in Nonhuman Primate Stroke
Stroke,
August 1, 2003;
34(8):
1994 - 1999.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ishikawa, D. Cooper, J. Russell, J. W. Salter, J. H. Zhang, A. Nanda, and D. N. Granger
Molecular Determinants of the Prothrombogenic and Inflammatory Phenotype Assumed by the Postischemic Cerebral Microcirculation
Stroke,
July 1, 2003;
34(7):
1777 - 1782.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. Lees, H.-C. Diener, K. Asplund, and M. Krams
UK-279,276, a Neutrophil Inhibitory Glycoprotein, in Acute Stroke: Tolerability and Pharmacokinetics
Stroke,
July 1, 2003;
34(7):
1704 - 1709.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. F. Maurus, D. Schmidt, M. K.J. Schneider, M. I. Turina, J. D. Seebach, and G. Zund
Hypoxia and reoxygenation do not upregulate adhesion molecules and natural killer cell adhesion on human endothelial cells in vitro
Eur. J. Cardiothorac. Surg.,
June 1, 2003;
23(6):
976 - 983.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mocco, T. Choudhri, J. Huang, E. Harfeldt, L. Efros, C. Klingbeil, V. Vexler, W. Hall, Y. Zhang, W. Mack, et al.
HuEP5C7 as a Humanized Monoclonal Anti-E/P-Selectin Neurovascular Protective Strategy in a Blinded Placebo-Controlled Trial of Nonhuman Primate Stroke
Circ. Res.,
November 15, 2002;
91(10):
907 - 914.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.J.M. Frijns and L.J. Kappelle
Inflammatory Cell Adhesion Molecules in Ischemic Cerebrovascular Disease
Stroke,
August 1, 2002;
33(8):
2115 - 2122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Gladstone, S. E. Black, and A. M. Hakim
Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions
Stroke,
August 1, 2002;
33(8):
2123 - 2136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Krishnadasan, C. R. Hampton, J. Griscavage-Ennis, R. J. Dabal, and E. D. Verrier
Molecular Mechanisms of Neurologic Injury Following Cardiopulmonary Bypass
Seminars in Cardiothoracic and Vascular Anesthesia,
March 1, 2002;
6(1):
43 - 53.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. J. Becker and D. L. Tirschwell
Ensuring Patient Safety in Clinical Trials for Treatment of Acute Stroke
JAMA,
December 5, 2001;
286(21):
2718 - 2719.
[Full Text]
[PDF]
|
|
|
|
